Shinaberger Christian S, Greenland Sander, Kopple Joel D, Van Wyck David, Mehrotra Rajnish, Kovesdy Csaba P, Kalantar-Zadeh Kamyar
Harold Simmons Center for Kidney Disease Research and Epidemiology, Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90509-2910, USA.
Am J Clin Nutr. 2008 Dec;88(6):1511-8. doi: 10.3945/ajcn.2008.26665.
Dietary restrictions to control serum phosphorus, which are routinely recommended to persons with chronic kidney disease, are usually associated with a reduction in protein intake. This may lead to protein-energy wasting and poor survival.
We aimed to ascertain whether a decline in serum phosphorus and a concomitant decline in protein intake are associated with an increase in the risk of death.
In a 3-y study (7/2001-6/2004) of 30 075 prevalent maintenance hemodialysis (MHD) patients, we examined changes in serum phosphorus and in normalized protein nitrogen appearance (nPNA), a surrogate of dietary protein intake, during the first 6 mo and the subsequent mortality. Four groups of MHD patients were defined on the basis of the direction of the changes in serum phosphorus and nPNA.
Baseline phosphorus had a J-shaped association with mortality, whereas higher baseline nPNA was linearly associated with greater survival. Compared with MHD patients whose serum phosphorus and nPNA both rose over 6 mo, those whose serum phosphorus decreased but whose nPNA increased had greater survival, with a case mix-adjusted death risk ratio of 0.90 (95% confidence limits: 0.86, 0.95; P < 0.001), whereas those whose phosphorus increased but whose nPNA decreased or those whose phosphorus and nPNA both decreased had worse mortality with a risk ratio of 1.11 (1.05,1.17; P < 0.001) and 1.06 (1.01,1.12; P = 0.02), respectively.
The risk of controlling serum phosphorus by restricting dietary protein intake may outweigh the benefit of controlled phosphorus and may lead to greater mortality. Additional studies including randomized controlled trials should examine whether nondietary control of phosphorus or restriction of nonprotein sources of phosphorus is safer and more effective.
对慢性肾病患者常规推荐的用于控制血清磷的饮食限制,通常会导致蛋白质摄入量减少。这可能会导致蛋白质 - 能量消耗及生存率降低。
我们旨在确定血清磷下降以及随之而来的蛋白质摄入量下降是否与死亡风险增加相关。
在一项针对30075例维持性血液透析(MHD)患者的为期3年(2001年7月 - 2004年6月)的研究中,我们检查了前6个月血清磷和标准化蛋白质氮呈现率(nPNA,饮食蛋白质摄入量的替代指标)的变化以及随后的死亡率。根据血清磷和nPNA的变化方向将MHD患者分为四组。
基线磷与死亡率呈J形关联,而较高的基线nPNA与更高的生存率呈线性相关。与血清磷和nPNA在6个月内均升高的MHD患者相比,血清磷下降但nPNA升高的患者生存率更高,病例组合调整后的死亡风险比为0.90(95%置信区间:0.86, 0.95;P < 0.001),而磷升高但nPNA下降的患者或磷和nPNA均下降的患者死亡率更差,风险比分别为1.11(1.05, 1.17;P < 0.001)和1.06(1.01, 答案:背景:对慢性肾病患者常规推荐的用于控制血清磷的饮食限制,通常会导致蛋白质摄入量减少。这可能会导致蛋白质 - 能量消耗及生存率降低。
我们旨在确定血清磷下降以及随之而来的蛋白质摄入量下降是否与死亡风险增加相关。
在一项针对30075例维持性血液透析(MHD)患者的为期3年(2001年7月 - 2004年6月)的研究中,我们检查了前6个月血清磷和标准化蛋白质氮呈现率(nPNA,饮食蛋白质摄入量的替代指标)的变化以及随后的死亡率。根据血清磷和nPNA的变化方向将MHD患者分为四组。
基线磷与死亡率呈J形关联,而较高的基线nPNA与更高的生存率呈线性相关。与血清磷和nPNA在6个月内均升高的MHD患者相比,血清磷下降但nPNA升高的患者生存率更高,病例组合调整后的死亡风险比为0.90(95%置信区间:0.86, 0.95;P < 0.001),而磷升高但nPNA下降的患者或磷和nPNA均下降的患者死亡率更差,风险比分别为1.11(1.05, 1.17;P < 0.001)和1.06(1.01, 1.12;P = 0.02)。
通过限制饮食蛋白质摄入量来控制血清磷的风险可能超过控制磷的益处,并可能导致更高的死亡率。包括随机对照试验在内的进一步研究应探讨非饮食方式控制磷或限制非蛋白质磷源是否更安全、更有效。 1.12;P = 0.02)。
通过限制饮食蛋白质摄入量来控制血清磷所带来的风险可能超过控制磷所带来的益处,并可能导致更高的死亡率。包括随机对照试验在内的进一步研究应探讨非饮食方式控制磷或限制非蛋白质磷源是否更安全、更有效。